Clinical Trial Update: Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of epirubicin and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Epirubicin (epirubicin)
• Rituximab (rituximab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED